Prophylactic eculizumab after renal transplantation in atypical hemolytic-uremic syndrome

N Engl J Med. 2010 May 6;362(18):1746-8. doi: 10.1056/NEJMc1001060.
No abstract available

Publication types

  • Case Reports
  • Letter
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Antibodies, Monoclonal / pharmacology
  • Antibodies, Monoclonal / therapeutic use*
  • Antibodies, Monoclonal, Humanized
  • Child
  • Complement Activation / drug effects
  • Complement C3 / metabolism
  • Complement Factor H / genetics
  • Complement Inactivating Agents / pharmacology
  • Complement Inactivating Agents / therapeutic use*
  • Graft Survival / drug effects*
  • Hemolytic-Uremic Syndrome / drug therapy
  • Hemolytic-Uremic Syndrome / surgery*
  • Humans
  • Kidney Transplantation*
  • Male
  • Mutation
  • Secondary Prevention

Substances

  • Antibodies, Monoclonal
  • Antibodies, Monoclonal, Humanized
  • Complement C3
  • Complement Inactivating Agents
  • Complement Factor H
  • eculizumab